Literature DB >> 10652169

Ocular findings after ivermectin treatment of patients with high Loa loa microfilaremia.

G Fobi1, J Gardon, M Santiago, D Ngangue, N Gardon-Wendel, M Boussinesq.   

Abstract

Hemorrhages in the palpebral conjunctiva (HPCs) have been recorded in patients living in an area endemic for loiasis who developed serious reactions after ivermectin treatment. A study was designed to evaluate the frequency of these lesions, and to identify risk factors associated with their appearance. The conjunctivae of 1,682 patients who complained of reactions were systematically examined. HPCs were found in 41 patients. The initial mean Loa loa microfilaremia in the individuals with HPCs was 14,900 microfilariae (mf) per mL, as compared with 14.5 mf/mL in the other patients. Mansonella perstans microfilaremia and male gender were also associated with HPCs. Post-treatment fundus examinations were performed on 37 patients, and a close relationship was found between the occurrence of HPCs and the presence of retinal lesions. The vascular pathological processes leading to the ocular lesions may be similar to those which occur at the cerebral level in patients harboring high L. loa microfilaremia who develop neurologic troubles after ivermectin treatment. Retinal lesions may represent a special feature of the Loa-related encephalopathies useful for differential diagnosis, and the HPCs may be useful as an alarm sign to identify those individuals who might develop serious reactions after ivermectin treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10652169

Source DB:  PubMed          Journal:  Ophthalmic Epidemiol        ISSN: 0928-6586            Impact factor:   1.648


  9 in total

1.  A controlled trial to assess the effect of quinine, chloroquine, amodiaquine, and artesunate on Loa loa microfilaremia.

Authors:  Joseph Kamgno; Patrick Nguipdop Djomo; Sébastien D Pion; Björn Thylefors; Michel Boussinesq
Journal:  Am J Trop Med Hyg       Date:  2010-03       Impact factor: 2.345

2.  Individual risk of post-ivermectin serious adverse events in subjects infected with Loa loa.

Authors:  Cédric B Chesnais; Sébastien D Pion; Charlotte Boullé; Jacques Gardon; Nathalie Gardon-Wendel; Joël Fokom-Domgue; Joseph Kamgno; Michel Boussinesq
Journal:  EClinicalMedicine       Date:  2020-10-10

3.  Case Report: Probable Case of Spontaneous Encephalopathy Due to Loiasis and Dramatic Reduction of Loa loa Microfilariaemia with Prolonged Repeated Courses of Albendazole.

Authors:  Divine B Arrey-Agbor; Hugues C Nana-Djeunga; Aude E Mogoung-Wafo; Mirabelle Mafo; Christian Danwe; Joseph Kamgno
Journal:  Am J Trop Med Hyg       Date:  2018-05-03       Impact factor: 2.345

4.  A possible case of spontaneous Loa loa encephalopathy associated with a glomerulopathy.

Authors:  Tuna Lukiana; Madone Mandina; Nanituma H Situakibanza; Marcel M Mbula; Bompeka F Lepira; Wobin T Odio; Joseph Kamgno; Michel Boussinesq
Journal:  Filaria J       Date:  2006-05-10

5.  Clinical picture, epidemiology and outcome of Loa-associated serious adverse events related to mass ivermectin treatment of onchocerciasis in Cameroon.

Authors:  Michel Boussinesq; Jacques Gardon; Nathalie Gardon-Wendel; Jean-Philippe Chippaux
Journal:  Filaria J       Date:  2003-10-24

6.  Possible pathogenic pathways in the adverse clinical events seen following ivermectin administration to onchocerciasis patients.

Authors:  Charles D Mackenzie; Timothy G Geary; John A Gerlach
Journal:  Filaria J       Date:  2003-10-24

7.  Effect of a Single Standard Dose (150-200 μg/kg) of Ivermectin on Loa loa Microfilaremia: Systematic Review and Meta-analysis.

Authors:  Sébastien D Pion; Jules Brice Tchatchueng-Mbougua; Cédric B Chesnais; Joseph Kamgno; Jacques Gardon; Jean-Philippe Chippaux; Stéphane Ranque; Jean-Christophe Ernould; André Garcia; Michel Boussinesq
Journal:  Open Forum Infect Dis       Date:  2019-01-11       Impact factor: 3.835

8.  Analysis of severe adverse effects following community-based ivermectin treatment in the Democratic Republic of Congo.

Authors:  Jean-Claude Makenga Bof; Daniel Muteba; Paul Mansiangi; Félicien Ilunga-Ilunga; Yves Coppieters
Journal:  BMC Pharmacol Toxicol       Date:  2019-08-16       Impact factor: 2.483

9.  A Test-and-Not-Treat Strategy for Onchocerciasis in Loa loa-Endemic Areas.

Authors:  Joseph Kamgno; Sébastien D Pion; Cédric B Chesnais; Matthew H Bakalar; Michael V D'Ambrosio; Charles D Mackenzie; Hugues C Nana-Djeunga; Raceline Gounoue-Kamkumo; Guy-Roger Njitchouang; Philippe Nwane; Jules B Tchatchueng-Mbouga; Samuel Wanji; Wilma A Stolk; Daniel A Fletcher; Amy D Klion; Thomas B Nutman; Michel Boussinesq
Journal:  N Engl J Med       Date:  2017-11-08       Impact factor: 91.245

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.